NASDAQ | ETF
Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from oncology.
The fund is non-diversified.
Top 15 Holdings
| Asset | Name | Sector | Industry | Weight |
|---|---|---|---|---|
| MRK | Merck & Company Inc | Healthcare | Drug Manufacturers - General | 5.45% |
| REGN | Regeneron Pharmaceuticals Inc | Healthcare | Biotechnology | 5.26% |
| 4568 | Daiichi Sankyo Co. Ltd. | Healthcare | Drug Manufacturers - General | 4.25% |
| AZN | AstraZeneca PLC | Healthcare | Drug Manufacturers - General | 3.97% |
| NOVN | Novartis AG | Healthcare | Drug Manufacturers - General | 3.59% |
| ILMN | Illumina Inc | Healthcare | Diagnostics & Research | 3.46% |
| CRSP | Crispr Therapeutics AG | Healthcare | Biotechnology | 3.29% |
| RVMD | Revolution Medicines Inc | Healthcare | Biotechnology | 3.18% |
| MREO | Mereo BioPharma Group PLC ADR | Healthcare | Biotechnology | 3.03% |
| IMGN | ImmunoGen Inc | Healthcare | Biotechnology | 3.00% |
| CLDX | Celldex Therapeutics Inc | Healthcare | Biotechnology | 2.99% |
| ARGX | argenx NV ADR | Healthcare | Biotechnology | 2.89% |
| 4519 | Chugai Pharmaceutical Co. Ltd. | Healthcare | Drug Manufacturers - General | 2.87% |
| EXAS | EXACT Sciences Corporation | Healthcare | Diagnostics & Research | 2.85% |
| GILD | Gilead Sciences Inc | Healthcare | Drug Manufacturers - General | 2.65% |